AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
7.38
+0.72 (10.81%)
At close: Jun 26, 2026, 4:00 PM EDT
7.39
+0.01 (0.14%)
After-hours: Jun 26, 2026, 7:58 PM EDT
AbCellera Biologics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for AbCellera Biologics stock have an average target of 9.40, with a low estimate of 7.00 and a high estimate of 13. The average target predicts an increase of 27.37% from the current stock price of 7.38.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for AbCellera Biologics stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 7 | 7 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BMO Capital | BMO Capital | Buy Maintains $7 | Buy | Maintains | $7 | -5.15% | Jun 18, 2026 |
| Truist Financial | Truist Financial | Buy Reiterates $10 → $12 | Buy | Reiterates | $10 → $12 | +62.60% | May 22, 2026 |
| JonesTrading | JonesTrading | Buy Reiterates $11 → $13 | Buy | Reiterates | $11 → $13 | +76.15% | May 12, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Reiterates $7 → $8 | Buy | Reiterates | $7 → $8 | +8.40% | May 12, 2026 |
| TD Cowen | TD Cowen | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 12, 2026 |
Financial Forecast
Revenue This Year
31.99M
from 75.13M
Decreased by -57.43%
Revenue Next Year
30.89M
from 31.99M
Decreased by -3.42%
EPS This Year
-0.65
from -0.49
EPS Next Year
-0.72
from -0.65
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 38.7M | 42.6M | |
| Avg | 32.0M | 30.9M | |
| Low | 25.8M | 6.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -48.5% | 33.3% | |
| Avg | -57.4% | -3.4% | |
| Low | -65.6% | -79.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.59 | -0.56 | |
| Avg | -0.65 | -0.72 | |
| Low | -0.71 | -0.80 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.